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INTRODUCTION: Papillary (PTC) and follicular (FTC) thyroid carcinomas, together known as differentiated
thyroid carcinomas (DTC), are among themost curable of cancers. Sites ofmetastases fromFTC are usually
osseous and those from PTC are in regional nodal basins and the lungs. Visceral metastases are rare and
when they do occur, they tend do so in multiple sites. We present the case of a patient with a follicular
variant of PTC and a solitary metastasis to the liver then review the relevant literature.
PRESENTATION OF CASE: An otherwise healthy 68-year-old woman was diagnosed with follicular variant
papillary thyroid cancer in 2003 and subsequently underwent thyroidectomy. The patient’s endocrinol-
ogist conducted surveillance of her thyroid cancer. In 2012, due to rise in thyroglobulin, a whole body
radioiodine scan was obtained which revealed an iodine-avid left liver lobe mass. Three cycles of radioio-
dine ablation therapy were unsuccessful and eventually the patient was referred for surgical resection.
Metastatic evaluation including a PET scan was negative with the exception of an isolated enhancing
4 cm mass in segment 4B of the liver. Anatomic segmental resection of liver was performed without
complications. Intraoperative ultrasonography was used to guide resection of the liver mass. Pathology
reports conﬁrmed metastatic follicular variant of PTC. Surgical margins were free of tumor. Patient was
dischargedhomeand is doingwell one year after surgery. The latest thyroglobulin levelwasundetectable.
DISCUSSION: Post-operative surveillance by PCP, endocrinologist or surgeon for patients with thyroid
carcinoma should be performed routinely. If identiﬁed, a solitary liver metastasis from primary thyroid
carcinoma should be considered for surgical resection. Due to sparse data available in literature, collect-
ing more data to establish algorithms for treatment of such rare metastatic cancers may be able to aid
physicians to achieve better outcomes.
CONCLUSION: Rare distant sites of metastases from DTC include eyes, pharynx, skin, muscle, ovaries,
adrenal glands, kidneys, esophagus, pancreas and liver. Isolated, resectable liver metastases from PTC are
exceedingly rare. Literature review revealed only 10 reported cases of liver metastases from DTC. As in
our patient, solitary liver metastasis from PTC should be considered for surgical resection which offers
the best chance for prolonged survival.
© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Papillary and follicular thyroid cancers, together, are referred
to as differentiated thyroid cancer (DTC) [1]. Differentiated thyroid
carcinomas are relatively raredespite common incidenceof thyroid
nodules [2]. Furthermore, thyroid carcinomas constitute less than
1% of all human cancers. The annual incidence world-wide ranges
from 0.5 to 10 cases per 100,000 population [1]. The median age
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at diagnosis is 45–50 years with two to four times more frequent
in women than men [1]. Fortunately, both papillary and follicu-
lar (differentiated) thyroid carcinomas are among the most curable
cancers. However, some patients are at higher risk for recurrent
disease or even death depending on the age at diagnosis, stage, cap-
sular involvement, nodal involvement, size and histological type.
Several factors inﬂuence pathogenesis of these cancers. Previous
studies report a high frequency (70%) of activating somatic alter-
ations of genes encoding effectors in the mitogen-activated protein
kinase (MAPK) signaling pathway, including point mutations of
BRAF and the RAS genes [14–18]. Rearrangements of the tyrosine
kinase domains of the RET and TRK genes with the amino-terminal
sequence of an unlinked gene are found in some papillary carcino-
http://dx.doi.org/10.1016/j.ijscr.2014.11.080
2210-2612/© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
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mas [1]. Additionally, activating point mutations of the RAS genes
are found with a similarly high frequency in thyroid adenomas and
follicular carcinomas, suggesting that RAS mutations represent an
early event in thyroid tumorigenesis [1]. Also, activating mutations
of the genes encoding the thyrotropin receptor and the ˛ subunit
of the stimulatory G (Gs) protein have been reported in some fol-
licular carcinomas [1,3]. And inactivating point mutations of the
p53 tumor-suppressor gene are rare in patients with differentiated
thyroid carcinomas, but common in those with undifferentiated
(anaplastic) thyroid carcinomas [3]. From an environmental stand
point, external irradiation to the neck during childhood increases
the riskofpapillary thyroid carcinoma.Amajor risk factor is ayoung
age at the time of irradiation; after the age of 15 or 20 years, the
risk is not increased [1]. Lastly, in countries where iodine intake
is adequate, differentiated cancers account for more than 80% of
all thyroid carcinomas, with the papillary histologic type being the
more frequent (accounting for 60–80% of cases) [1]. There is no
increase in the incidence of thyroid carcinomas in countries where
iodine intake is low, but there is a relative increase in follicular and
anaplastic carcinomas [2,3]. From a genetic perspective, in non-
sporadic cases, a higher incidence of papillary carcinomas has been
reported in patients with adenomatous polyposis coli and Cow-
den’s disease (the multiple hamartoma syndrome) [3]. About 3% of
cases of papillary carcinoma are familial. In this case report, the pri-
mary focus will be papillary carcinoma which is an unencapsulated
tumor with papillary and follicular structures that is character-
ized by overlapping nuclei that have a ground-glass appearance
and longitudinal grooves, with invaginations of cytoplasm [1–3].
Encapsulated, follicular, tall-cell, columnar-cell, clear-cell, and dif-
fuse sclerosing carcinomas are recognized histologic variants; they
are classiﬁed as papillary carcinomas because of their characteristic
nuclear features.
Isolated metastasis to the liver from thyroid cancer is a rare
event with a reported frequency of less than 0.5% [3]. Metastatic
liver involvement from differentiated thyroid cancer, both follicu-
lar and papillary, is nearly always multiple or diffuse and usually
found along with other distant metastases including the lungs,
bones and the brain) [4–12]. Locations with very rare incidence
of metastases include eyes, pharynx, skin, muscle, ovaries, adrenal
glands, kidneys, esophagus, pancreas and livermetastasis. A review
of the literature revealed that only ten cases of all liver metas-
tases from DTC have been documented, with a rate of 0.5% or
less. Three patients were men and seven were women. Their aver-
age age was 63 years (range from 32 to 85 years). Histologically,
the primary tumor was identiﬁed as papillary in four patients,
follicular in ﬁve and Hürthle cell thyroid cancer in one patient
[3]. In two cases, the metastatic histological type was inconsis-
tent with the primary tumor. The primary tumors were FTC and
PTC, while both their metastatic lesions were a FV-PTC [3]. What
makes the case presented here in an interesting one is the fact that
thyroid cancer metastases to liver are rare, and even more so is
an isolated and resectable solitary liver metastases from thyroid
cancer.
2. Methods
This is a retrospective case report and a review of the literature.
Our patient’s evaluation and surgical intervention were performed
at Scottsdale Healthcare, in Scottsdale, Arizona, USA.
3. Results
The patient is an otherwise healthy 68-year-old woman with a
history of follicular variant papillary thyroid cancer diagnosed in
Fig. 1. Positron emission tomography (PET) scan demonstrates an isolated focus of FDG uptake in the liver indicating an isolated metastatic focus of tumor.
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2003 and breast cancer diagnosed in 2005. Patient had no cardiac,
pulmonary or renal diseases. Patient had no history of diabetes or
hypertension. In 2003, the patient had a total thyroidectomy for
thyroid cancer. In 2005, she had a modiﬁed radical mastectomy
for stage I breast cancer and did not receive radiation therapy or
chemotherapy. The patient was under the care of an endocrinolo-
gist for surveillance of her thyroid cancer. In 2012, a whole body
radioiodine scan done to monitor the patient for thyroid cancer
recurrence or metastases revealed a radioiodine-avid mass in the
medial left lobe of the liver, presumably a solitary hematogenous
metastasis. Patient thenunderwent three separate bouts of radioio-
dine ablation therapy for a total of 425mCi. The patient received
ablation post RAI ablation after her original thyroid surgery and a
subsequent RAI treatment due to persistent low level thyroglobu-
lin elevation. Her thyroglobulin level remained undetectable until
the current illness, duringwhich it rose dramatically. Accordingly, a
third RAI therapy was administered and the post-RAI scan revealed
only the very radioiodine avid lesion in the liver. Because this was
so intense, isolated and could possibly have obscured imaging of
other foci of metastatic tumor, a PET CT scan was performed, that
revealed only the single liver metastasis. A fourth 131I dose was
administered and while it resulted in a reduced the thyroglobu-
lin level, the solitary lesion in the liver remained. Consultations
with medical oncology, radiation oncology, interventional radiol-
ogy and surgery obtained with the resultant consensus that the
best option was surgical resection Fig. 1. The patient underwent an
anatomic segment 4B liver resection for a 4 cm isolated tumormass
without complications. Intraoperative ultrasonography was used
to assess the liver mass (Fig. 2). Fig. 3(a–d) describes the patholog-
ical ﬁndings of the metastasis. The gross hepatic metastasis seen
intraopratively is shown in Fig 3a. The hepatic resection speci-
men (Fig. 3b) showed a bulging ovoid subserosal nodule measuring
Fig. 2. Intraoperative ultrasonography was used to assess the liver mass.
4.3 cm in greatest dimension. The mass was well-demarcated from
the surrounding hepatic tissue and showed a variegated tan to
red–brown cut surface with punctate areas of yellow discoloration.
Microscopic evaluation of routine hematoxylin and eosin-stained
sections showed a neoplasm with a follicular architecture consis-
tent with metastatic thyroid carcinoma (Fig 3c). Tumor nuclei were
enlarged and frequently showed irregular contours. Chromatinwas
ﬁne and, in some cells, inconspicuous. Many cells showed nuclear
grooves. Nuclear inclusions were not identiﬁed. The microscopic
features were consistent with metastatic well-differentiated thy-
Fig. 3. (a–d) Describes the pathological ﬁndings of the metastasis.
The gross appearance of the hepatic metastasis seen intraopratively is shown in Fig. 3a.
The hepatic resection specimen (Fig. 3b) showed a bulging ovoid subserosal nodule, with in the liver, measuring 4.3 cm in greatest dimension.
Microscopic evaluation of routine hematoxylin and eosin-stained sections showed aneoplasmwith a follicular architecture (Fig. 3c). The cellswere cuboidalwith pleomorphic
nuclei which frequently showed deep indentations or grooves. Nuclear chromatin was ﬁne and nucleoli were inconspicuous. Intranuclear pseudoinclusions were not seen.
Within the follicles was homogeneous eosinophilic material. The morphologic features were highly suggestive of metastatic papillary thyroid carcinoma (follicular variant).
This impression was conﬁrmed by immunohistochemical stains showing nuclear staining for TTF-1 (Fig. 3d) and cytoplasmic positivity for thyroglobulin (not shown).
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roid carcinoma and in particular, appeared most consistent with
the follicular variant of papillary thyroid carcinoma. Immuno-
histochemical stains showed expression of TTF-1 (Fig. 3d) and
thyroglobulin (not shown), supporting the diagnosis of metastatic
thyroid carcinoma. Surgical margins were free of involvement with
tumor. Patient was discharged home and has been doing well for
12 months after her operation. At this last clinic visit, her TSH-
stimulated thyroglobulin and thryglobulin antibodies levels remain
undetectable. The prognostic signiﬁcance of the presence of RAS
or BRAF mutations remains controversial so testing was not done.
Presently, the authors would perform mutational analysis of BRAF
as an adjunct to either diagnose or conﬁrm PTC on equivocal FNA
and if a patient has unresectable metastases that are refractory-to-
radioiodine in order to discern whether or not the treatment with
a BRAF inhibitor would be indicated.
4. Discussion
Liver metastasis from differentiated thyroid cancer are quite
rare, with a reported frequency of 0.5% [3,13]. Even more unusual
are isolated resectable liver metastases from papillary thyroid
cancer. The patient presented herein, ﬁts well the typical epidemi-
ological descriptors of previously reported cases: our patient was
female, 68 years old, and had a follicular variant of papillary thy-
roid carcinoma. As noted in a recent study in 2011 by Hong-Jun
Song et al. “. . .only ten cases have been documented in the liter-
ature; three were males and seven were females, with an average
age of about 63 years (range from32 to 85 years). Histologically, the
primary tumor was identiﬁed as papillary in four patients, follicu-
lar in ﬁve patients, and Hürthle cell thyroid cancer in one patient.”
Post-operative surveillance by PCP, endocrinologist or surgeon for
patients with thyroid carcinoma should be complete and include
appropriate imaging modalities when metastasis is suspected. PET,
CTandultrasonography remain the standard imagingoptions.Once
identiﬁed, a solitary liver metastasis from primary thyroid carci-
noma should be considered for surgical resection in the appropriate
clinical scenario. In addition, a compilation of the reported cases of
solitary visceralmetastasis from thyroid carcinoma should be stud-
ied and evaluated for success of surgical resection, prognosis, rate
of survival, and size of metastatic lesions in each histological type
of thyroid carcinoma. Collecting more data to establish algorithms
for treatment of such rare cancers may be able to aid physi-
cians to better utilize diagnostic tests, surveillance and ultimately
to provide more deﬁnitive care for those who suffer from rare
diseases.
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